학술논문

Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2021, 39 15, 4p. Supplement: S
Subject
Language
English
ISSN
15277755